Terms: = Breast cancer AND CEP17 AND Treatment
61 results:
1. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.
Peg V; Moline T; Roig M; Saruta Y; Cajal SRY
Diagn Pathol; 2024 Feb; 19(1):32. PubMed ID: 38360676
[TBL] [Abstract] [Full Text] [Related]
2. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract] [Full Text] [Related]
3. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract] [Full Text] [Related]
4. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract] [Full Text] [Related]
5. A clinicopathological study and survival analysis of 99 breast cancers with HER2/cep17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China.
Zhou S; Lv H; Li A; Li M; Zhong S; Lu H; Zhou X; Bai Q; Yang W
BMC Cancer; 2023 Jan; 23(1):84. PubMed ID: 36698078
[TBL] [Abstract] [Full Text] [Related]
6. Using the HER2/cep17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ breast cancer.
Lander EM; Rappazzo KC; Huang LC; Hu JR; Chen H; Shyr Y; Abramson VG
Oncologist; 2023 Feb; 28(2):123-130. PubMed ID: 36495309
[TBL] [Abstract] [Full Text] [Related]
7. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified breast cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and Pathologic Features Associated With Invasive breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [cep17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract] [Full Text] [Related]
9. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract] [Full Text] [Related]
10. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Antolín S; García-Caballero L; Reboredo C; Molina A; Mosquera J; Vázquez-Boquete Á; Gallego R; Santiago MP; Concha Á; Pérez E; Calvo L; García-Caballero T
Virchows Arch; 2021 Oct; 479(4):853-857. PubMed ID: 33934230
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish breast cancer Group (DBCG).
Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
[TBL] [Abstract] [Full Text] [Related]
12. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract] [Full Text] [Related]
13. Triple-Positive breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J; Edelweiss M; Ross DS; Xu B; Moo TA; Brogi E; D'Alfonso TM
Arch Pathol Lab Med; 2021 Jun; 145(6):728-735. PubMed ID: 33112958
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract] [Full Text] [Related]
16. [Relationship between HER2 Gene Amplification and the Therapeutic Effect of Pertuzumab in HER2-Positive breast cancer].
Nakamura Y; Takuwa H; Takeuchi M
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1193-1195. PubMed ID: 32829353
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
Blanton KC; Deal AM; Kaiser-Rogers KA; Anders CK; O'Connor SM; Hertel JD; Calhoun BC
Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic Value of HER2 to cep17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory breast cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract] [Full Text] [Related]
19. [HER2/neu gene amplification as a mechanism of clonal heterogeneity in breast cancer].
Pavlenko IA; Zavalishina LE; Povilaitite PE
Arkh Patol; 2019; 81(6):49-55. PubMed ID: 31851192
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive breast cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract] [Full Text] [Related]
[Next]
